Cannabis Testing Leader EVIO Inc. (EVIO) Marks Notable

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
486
Cannabis Testing Leader EVIO Inc. (EVIO) Marks Notable Milestones in California, Oregon and Canada

EVIO has completed its acquisition of the award-winning MRX Labs in Oregon

The company signed a five-year lease agreement for a facility in the cannabis cultivation hotbed of Palm Desert, California
EVIO has announced the filing and receipt of its preliminary non-offering prospectus with the Ontario Securities Commission in Canada
It’s been a busy summer for leading North American cannabis testing and scientific research provider EVIO Inc. (OTCQB: EVIO), which specializes in providing state-mandated ancillary services to ensure the quality and safety of America’s cannabis supply. The company recently acquired an award-winning testing lab in Oregon, has expanded its California footprint with a five-year lease for a new facility in Palm Desert, California, and has announced the filing and receipt of its preliminary non-offering prospectus with the Ontario Securities Commission in Canada.

MRX Labs Acquisition

On July 11, EVIO announced the completion of a previously announced acquisition of MRX Labs, an award-winning testing lab based in Oregon. EVIO has acquired 100 percent of MRX Labs’ assets, which include equipment, real estate, customer lists, customer contracts, rental agreements and equipment leases (http://nnw.fm/x2HiD).

The EVIO Labs Portland facility will be moving its personnel and operation license to what has formerly been the MRX Labs Tigard location. The new lab will operate under the name EVIO Labs Portland. Through this move, EVIO will gain additional operating capacity and add statewide business contacts and customers.

EVIO will build on MRX Labs’ reputation of exceptional customer care and service and will work diligently to make the transition smooth and seamless for MRX Labs’ customers. EVIO will be able to provide clients with the same services they have enjoyed through MRX Labs and will also be better equipped operationally to provide all state-mandated cannabis tests in-house for clients throughout Oregon.

Lease Agreement for Palm Desert Facility

On July 10, EVIO announced the expansion of its California footprint with the signing of a five-year lease agreement for a 7,370-square-foot facility in Palm Desert, California (http://nnw.fm/m5FHZ).

The company’s new facility is located centrally to Desert Hot Springs and Coachella and is strategically positioned among the largest cannabis cultivators in Southern California. Marijuana manufacturing operations are not currently taxed there, due to a prior vote by the Desert Hot Springs City Council, and this has attracted many operators to the area.

Desert Hot Springs was the first Southern California city to legalize large-scale cannabis cultivation—a move that caused the surrounding area to be flooded with marijuana growers and developers. Through the signing of its lease for the new Palm Desert Facility, EVIO has entered this leading hub for powerful players within the cannabis industry, like the Coachella Valley Cannabis Alliance Network, and will benefit from being among business leaders who recognize the economic opportunities cannabis brings.

The facility will provide comprehensive compliance testing services as well as research and development for new marijuana products. California recently imposed a July 1 testing deadline that mandated licensed cannabis retailers to only sell lab-tested products. Because of this, EVIO expects to see a substantial increase in the demand for cannabis testing services, and, in anticipation, the company plans to have the Palm Desert facility operational by fall 2018.

Preliminary Non-Offering Prospectus Filing

EVIO also recently announced the filing and receipt of its preliminary non-offering prospectus with the Ontario Securities Commission (http://nnw.fm/F31kd). This filing was a requirement for EVIO to qualify to become a reporting issuer in Ontario, Canada.

Contained in the preliminary prospectus was important information regarding EVIO and its currently issued securities. The preliminary prospectus is subject to amendment, as may be required by the OSC. Once a review has been completed by the OSC and comments provided regarding the preliminary prospectus, EVIO will move forward with filing its non-offering (final) prospectus with the OSC. As soon as EVIO receives the final receipt for the final prospectus, the company will apply to have its common shares listed on the Canadian Securities Exchange.

For more information, visit the company’s website at www.EVIOLabs.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

EVIO Inc (EVIO) Stock Research Links

EVIO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading